Treating Prostate Cancer in Older Patients

Video

This video reviews the management approach for prostate cancer in older patients, including when screening is appropriate and how geriatric assessments can guide treatment decisions.

In this video, William Dale, MD, PhD, of the City of Hope Cancer Center in Duarte, California, discusses the management approach for prostate cancer in older patients, including when screening is appropriate and how geriatric assessments can guide treatment decisions.

Dale spoke on this topic during an education session, “Disparities in Screening and Treatment of Prostate Cancer for the Older Patient,” at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting last month in Chicago.

Recent Videos
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Related Content
No treatment-related deaths were observed with radiotherapy for extensive-stage small cell lung cancer, and most adverse effects were grade 1 or 2.

Consolidative Thoracic Radiotherapy Displays Safety, Efficacy in ES-SCLC

Roman Fabbricatore
August 20th 2025
Article

No treatment-related deaths were observed with radiotherapy for extensive-stage small cell lung cancer, and most adverse effects were grade 1 or 2.

Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.

The primary end point of the trial was PFS. Secondary end points included OS, ORR, and the toxicity profile of nivolumab with carboplatin/cisplatin and etoposide.

Nivolumab Plus Chemo Improved OS and PFS in Front-Line ES-SCLC

Tim Cortese
August 20th 2025
Article

The median PFS and OS were 5.5 months and 11.2 months with nivolumab plus carboplatin/cisplatin and etoposide in patients with small cell lung cancer.

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

Therapy with anti-CD38 monoclonal antibodies significantly increased the minimal residual disease–negative rate.

Further Research on Anti-CD38 mAbs Warranted in Multiple Myeloma

Tim Cortese
August 19th 2025
Article

A systematic review of 8 randomized trials showed that anti-CD38 monoclonal antibodies did not improve overall survival in high-risk subgroups.

No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.

Tuspetinib Exhibits Enhanced Efficacy in Diverse Newly Diagnosed AML Group

Roman Fabbricatore
August 19th 2025
Article

No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.